Logo

27th EHA June 9–12, 2022
From Vienna to Switzerland

Abstracts and slide decks for daratumumab, ibrutinib, teclistamab, talquetamab, and cilta-cel

Recently, at the European Hematology Association Congress (EHA) 2022, the latest discoveries and advances within the treatment of hematologic diseases were presented.

Below, links to the listed abstracts, original posters, and corresponding slide deck presentations are provided.

For further readings on treatment opportunities on multiple myeloma and chronic lymphocytic leukemia

Ibrutinib
Chronic Lymphocytic Leukemia
REALITY study

Evaluation of the effectiveness of ibrutinib as 1st, 2nd, or ≥ 3rd treatment option in patients with CLL during clinical practice in Germany.1

Daratumumab
Multiple Myeloma
MAIA subgroup analysis

Subgroup analysis of transplant-ineligible patients with newly diagnosed MM in the MAIA study evaluating the effect of daratumumab plus lenalidomide and dexamethasone.2

Post-hoc analysis of CASTOR and POLLUX study

Evaluating efficacy of daratumumab plus Rd versus Vd in subgroups with relapsed or refractory MM in post-hoc analyses of CASTOR and POLLUX studies.3

Abbreviations

ALL Acute Lymphoblastic Leukemia

B Bendamustine

BCL-2 B-Cell Lymphoma 2

BCMA B-Cell Maturation Antigen

BR Bendamustine and Rituximab

CLL Chronic Lymphocytic Leukemia

EHR Electronic Health Record

LL Lymphoblastic Leukemia

MCL Mantle Cell Lymphoma

MM Multiple Myeloma

MRD Minimal Residual Disease

ORR Overall Response Rate

PFS Progression-Free Survival

R Rituximab

Rd Lenalidomide and Dexamethasone

RVd Rituximab and Bortezomib and Dexamethasone

RWE Real World Evidence

SoC Standard of Care

Vd Bortezomib and Dexamethasone

References
  1. Welslau M et al. REAL WORLD OUTCOME WITH IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE GERMAN REALITY STUDY. EHA June 2022. Poster presentation #P636.
  2. Facon T et al. TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY. EHA June 2022. Poster presentation #P936.
  3. Spencer A et al. DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY. EHA June 2022. Poster presentation #P933.

References can be requested from Janssen-Cilag AG.

Fachinformation IMBRUVICA®: http://www.swissmedicinfo.ch

Fachinformation DARZALEX®: http://www.swissmedicinfo.ch

EM-103889 - July 2022